ea0026p79 | Endocrine tumours and neoplasia | ECE2011
Horsch D
, Kocha W
, Lincy J
, Saletan S
, Lombard-Bohas C
Background: In the phase III RADIANT-3 trial, everolimus, an oral mTOR inhibitor, demonstrated superiority in progression-free survival with a median of 11.0 vs 4.6 months for placebo (hazard ratio, 0.35; 95% confidence interval, 0.27 to 0.45; P<0.0001) in patients with advanced pNET (ESMO 2010, Abstract #LBA9). Here we present an update of the safety analysis from this trial.Methods: Patients with progressive advanced low- or intermediate-gra...